Table 1.
Definitions of disease activity used in the analysis.
Table 2.
Baseline characteristics of the SPMS and PPMS subjects included in the analysis.
Figure 1.
Heat map display of disease activity at the individual level.
The heat maps have patients on columns, and outcome measures on rows. Red indicates intermittent activity or progression, green indicates improvement, black indicates no change, and white indicates missing value. The data are from 2-year studies in SPMS (panel A) and PPMS (panel B) subjects randomized to placebo in the IMPACT [8] and OLYMPUS [9] multicenter clinical trials. All calculations were performed based on the definitions listed in Table 1. Notice that progression was most often detected using definition 2 with the T25FW and the 9HP.
Table 3.
Comparison of disease activity over 2 years in placebo SPMS versus placebo PPMS by various definitions of intermittent activity, progression, and improvement.
Figure 2.
Hierarchical clustering analysis of disease progression using consistent worsening of physical and cognitive function using the multiple sclerosis functional composite.
Consistent worsening was determined by using the progression 2 definition (at least 6/8 worse than baseline; Table 1). Study subjects are on columns. Red indicates “progressor”, blue indicates lack of progression. The data are from 2-year studies in SPMS (a) and PPMS (b) subjects randomized to placebo in the IMPACT [8] and OLYMPUS [9] clinical trials.
Table 4.
Frequency of patient reported progression and improvement in English speaking subjects with SPMS from the IMPACT study.